Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/28930
Title: | Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers. | Authors: | Bera O.;Fourme-Mouret E.;Fricker J.-P.;Lasset C.;Bonadona V.;Berthet P.;Faivre L.;Luporsi E.;Mari V.;Gladieff L.;Sobol H.;Eisinger F.;Longy M.;Dugast C.;Colas C.;Coupier I.;Corsini C.;Vennin P.;Adenis C.;Nguyen T.D.;Delnatte C.;Tinat J.;Tennevet I.;Limacher J.-M.;Maugard C.;Bignon Y.-J.;Demange L.;Penet C.;Cohen-Haguenauer O.;Venat-Bouvet L.;Leroux D.;Dreyfus H.;Zattara-Cannoni H.;Fert-Ferrer S.;Nogues C.;Gauthier-Villars M.;Caron O.;Gesta P.;Pujol P.;Lortholary A.;Ellis S.;Barrowdale D.;Frost D.;Evans D.G.;Izatt L.;Adlard J.;Eeles R.;Brewer C.;Tischkowitz M.;Henderson A.;Cook J.;Eccles D.;Hogervorst F.B.L.;Collee J.M.;Van Asperen C.J.;Mensenkamp A.R.;Meijers-Heijboer H.E.J.;Blok M.J.;Oosterwijk J.C.;Verloop J.;Van Den Broek E.;Van Engelen K.;Mourits M.J.E.;Ausems M.G.E.M.;Koppert L.B.;Hopper J.L.;John E.M.;Chung W.K.;Andrulis I.L.;Daly M.B.;Buys S.S.;Benitez J.;Caldes T.;Jakubowska A.;Simard J.;Singer C.F.;Tan Y.;Olah E.;Navratilova M.;Foretova L.;Gerdes A.-M.;Roos-Blom M.-J.;Van Leeuwen F.E.;Arver B.;Olsson H.;Schmutzler R.K.;Engel C.;Kast K.;Phillips K.-A.;Terry M.B.;Milne R.L.;Goldgar D.E.;Rookus M.A.;Andrieu N.;Easton D.F.;Mavaddat N.;Antoniou A.C.;Mooij T.M.;Hooning M.J.;Heemskerk-Gerritsen B.A.;Laborde L.;Breysse E.;Stoppa-Lyonnet D.;Buecher B. | Institution: | (Mavaddat, Antoniou, Barrowdale, Frost, Easton) Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Worts Causeway, Cambridge CBI 8RN, United Kingdom (Mooij, Roos-Blom, Van Leeuwen, Rookus) Department of Epidemiology, Netherlands Cancer Institute, P.O. Box 90203, Amsterdam 1006 BE, Netherlands (Hooning, Heemskerk-Gerritsen) Department of Medical Oncology, Family Center Clinic, Erasmus MC Cancer Institute, Rotterdam, Netherlands (Nogues) DASC, Oncogenetique Clinique, Institut Paoli-Calmettes, Marseille, France (Gauthier-Villars) Institut Curie, Service de Genetique, Paris, France (Caron) Departement de Medecine Oncologique, Gustave Roussy Hopital Universitaire, Villejuif, France (Gesta) Centre Hospitalier, Service Regional d'Oncologie Genetique Poitou-Charentes, Niort, France (Pujol) Unite d'Oncogenetique, CHU Arnaud de Villeneuve, Montpellier, France (Lortholary) Centre Catherine de Sienne, Service d'Oncologie Medicale, Nantes, France (Evans) Genomic Medicine, Manchester Academic Health Sciences Centre, Division of Evolution and Genomic Sciences, Manchester University, Central Manchester, University Hospitals NHS Foundation Trust, Manchester, United Kingdom (Izatt) Clinical Genetics, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom (Adlard) Yorkshire Regional Genetics Service, Chapel Allerton Hospital, University of Leeds, Leeds, United Kingdom (Eeles) Oncogenetics Team, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom (Brewer) Department of Clinical Genetics, Royal Devon and Exeter Hospital, Exeter, United Kingdom (Tischkowitz) Academic Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, United Kingdom (Henderson) Institute of Genetic Medicine, Centre for Life, Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom (Cook) Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, United Kingdom (Eccles) University of Southampton Faculty of Medicine, Southampton University Hospitals NHS Trust, Southampton, United Kingdom (Van Engelen) Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Coordinating Center: Netherlands Cancer Institute, Amsterdam, Netherlands (Van Engelen) Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands (Mourits) Department of Gynaecological Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands (Ausems) Department of Genetics, University Medical Center Utrecht, Utrecht, Netherlands (Koppert) Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands (Hopper, Phillips, Milne) Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC 3010, Australia (John) Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, United States (Chung) Departments of Pediatrics and Medicine, Columbia University Medical Center, New York, NY, United States (Chung, Terry) Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, United States (Andrulis) Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada (Andrulis) Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada (Daly) Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, United States (Buys) Department of Medicine, Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, United States (Buys) Research Department, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (Phillips) Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia (Benitez) Human Genetics Group and Genotyping Unit, CEGEN, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain (Caldes) Molecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC, CIBERONC (ISCIII), Madrid, Spain (Jakubowska) Department of Genetics and Pathology, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, Poland (Jakubowska) Independent Laboratory of Molecular Biology and Genetic Diagnostics, Pomeranian Medical University, Unii Lubelskiej 1, Szczecin, Poland (Simard) Genomics Center, Centre Hospitalier Universitaire de Quebec, Universite Laval Research Center, 2705 Laurier Boulevard, Quebec City, Quebec, Canada (Singer, Tan) Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, Vienna A 1090, Austria (Olah) Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary (Navratilova, Foretova) Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 65653, Czechia (Gerdes) Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (Arver) Department of Oncology and Pathology, Karolinska Institute, Stockholm 171 76, Sweden (Arver, Olsson) Department of Oncology, Lund University Hospital, Lund, Sweden (Schmutzler) Center for Familial Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany (Schmutzler) Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany (Engel) Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany (Kast) Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universitat Dresden, Dresden, Germany (Kast) National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany (Kast) German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany (Phillips) Department of Medical Oncology Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, East Melbourne, VIC 8006, Australia (Terry) Department of Epidemiology, Columbia University, New York, NY, United States (Milne) Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia (Milne) Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia (Goldgar) Department of Dermatology, University of Utah School of Medicine, 30 North 1900 East, SOM 4B454, Salt Lake City, UT 841232, United States (Andrieu) INSERM, U900, Paris, France (Andrieu) Institut Curie, Paris, France (Andrieu) Mines Paris Tech, Fontainebleau, France (Andrieu) PSL Research University, Paris, France (Easton) Centre for Cancer Genetic Epidemiology, Department of Oncology, Strangeways Research Laboratory, University of Cambridge, Worts Causeway, Cambridge CBI 8RN, United Kingdom | Issue Date: | 9-Nov-2020 | Copyright year: | 2020 | Publisher: | BioMed Central Ltd (United Kingdom. E-mail: info@biomedcentral.com) | Place of publication: | United Kingdom | Publication information: | Breast Cancer Research. 22 (1) (no pagination), 2020. Article Number: 8. Date of Publication: 16 Jan 2020. | Journal: | Breast Cancer Research | Abstract: | Background: The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. Method(s): A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. Result(s): There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94-1.61) or BRCA2 (HR = 0.88; 95% CI 0.62-1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40-1.15) and 1.07 (95% CI 0.69-1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26-0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. Conclusion(s): We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.Copyright © 2020 The Author(s). | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1186/s13058-020-1247-4 | PubMed URL: | 31948486 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31948486] | ISSN: | 1465-5411 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/28930 | Type: | Article | Subjects: | postmenopause *tumor suppressor gene time factor *salpingooophorectomy *heterozygote human major clinical study *menopause patient care patient counseling premenopause *risk reduction risk assessment retrospective study prospective study adult age aged article *breast cancer cancer growth cancer incidence *cancer risk cohort analysis controlled study disease association female follow up gene function *gene mutation genetic analysis genetic association genetic risk *tumor suppressor gene retrospective study risk assessment *risk reduction *salpingooophorectomy time factor adult age aged Article *breast cancer cancer growth cancer incidence *cancer risk cohort analysis controlled study disease association female follow up gene function *gene mutation genetic analysis genetic association genetic risk *heterozygote human major clinical study *menopause patient care patient counseling postmenopause premenopause prospective study |
Type of Clinical Study or Trial: | Observational study (cohort, case-control, cross sectional or survey) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.